Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 1.67B | 1.68B | 1.61B | 1.34B | 1.19B |
Gross Profit | 333.90M | 1.28B | 576.70M | 492.30M | 398.50M |
EBITDA | 378.30M | 390.60M | 402.10M | 392.00M | 324.30M |
Net Income | 191.20M | 183.60M | 224.70M | 234.60M | 173.60M |
Balance Sheet | |||||
Total Assets | 2.65B | 2.71B | 2.78B | 1.86B | 1.74B |
Cash, Cash Equivalents and Short-Term Investments | 334.20M | 359.70M | 328.90M | 274.60M | 246.20M |
Total Debt | 1.03B | 1.12B | 1.08B | 465.20M | 509.10M |
Total Liabilities | 1.44B | 1.55B | 1.62B | 853.20M | 889.10M |
Stockholders Equity | 1.21B | 1.16B | 1.17B | 1.01B | 851.30M |
Cash Flow | |||||
Free Cash Flow | 238.50M | 193.20M | 113.70M | 204.20M | 202.40M |
Operating Cash Flow | 312.80M | 298.60M | 231.20M | 268.30M | 252.00M |
Investing Cash Flow | -65.30M | -95.70M | -576.60M | -62.10M | -52.50M |
Financing Cash Flow | -215.00M | -219.20M | 362.20M | -204.80M | -143.90M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
81 Outperform | £7.33B | 24.96 | 13.99% | 1.28% | 6.10% | 33.05% | |
78 Outperform | £5.15B | 21.66 | 23.50% | 1.48% | 0.64% | 4.92% | |
74 Outperform | £4.36B | 22.80 | 16.16% | 2.96% | -1.03% | 4.06% | |
74 Outperform | £6.36B | 20.38 | 17.83% | 1.32% | -4.95% | 36.95% | |
71 Outperform | £2.68B | 26.45 | 17.03% | 2.29% | 4.91% | -7.75% | |
68 Neutral | £2.94B | 10.24 | 8.40% | 3.45% | 2.87% | -9.95% | |
56 Neutral | £6.62B | ― | -1.53% | 1.54% | 3.52% | -24.01% |
Spirax Group plc has announced recent transactions involving its senior management under the company’s employee share schemes. These transactions, conducted in accordance with the UK Market Abuse Regulation, include acquisitions of partnership and matching shares as well as a restructuring of shareholding by one of the managing directors. The transactions were executed on the London Stock Exchange and involve key figures such as the Group CEO, HR Director, and Sustainability Director, reflecting ongoing internal financial activities within the company.
The most recent analyst rating on (GB:SPX) stock is a Buy with a £7850.00 price target. To see the full list of analyst forecasts on Spirax Sarco Engineering stock, see the GB:SPX Stock Forecast page.
At the recent Annual General Meeting of Spirax Group plc, all resolutions were successfully passed, reflecting strong shareholder support for the company’s strategic direction. The meeting’s outcomes, including the approval of special resolutions, underscore the company’s commitment to its growth and sustainability objectives, aligning with its role in advancing industrial efficiency and decarbonization efforts. The resolutions will be made available for inspection and filed with relevant authorities, ensuring transparency and compliance.
The most recent analyst rating on (GB:SPX) stock is a Buy with a £7850.00 price target. To see the full list of analyst forecasts on Spirax Sarco Engineering stock, see the GB:SPX Stock Forecast page.
Spirax Sarco Engineering has maintained its full-year guidance despite a challenging economic environment marked by negative industrial production growth in key European markets and macroeconomic uncertainties due to trade tariffs. The company has focused on operational priorities such as consultative solution-selling, manufacturing improvements, and restructuring, which is expected to yield significant annual savings. While demand trends remain consistent with previous forecasts, the company anticipates stronger revenue growth and profit margins in the second half of the year, driven by increased MRO and solution sales and the recovery of Biopharm and Semicon sectors.
The most recent analyst rating on (GB:SPX) stock is a Buy with a £7850.00 price target. To see the full list of analyst forecasts on Spirax Sarco Engineering stock, see the GB:SPX Stock Forecast page.
Spirax Group plc announced the acquisition of shares by key executives under the company’s Share Incentive Plan. This transaction reflects the company’s ongoing commitment to aligning the interests of its leadership with shareholders. The acquisitions were conducted on the London Stock Exchange, with each executive acquiring a combination of Partnership and Matching Shares, signaling confidence in the company’s future performance.
Spirax Group plc announced a change in its board as Tim Cobbold stepped down from the board of TI Fluid Systems plc following its acquisition by ABC Technologies Acquisitions Limited. This change reflects the company’s ongoing strategic adjustments and may impact its governance and stakeholder relationships.
Spirax Group plc announced recent transactions related to its employee share schemes, in compliance with UK Market Abuse Regulation. Additionally, Maria Antoniou will join the board as a Non-Executive Director and Chair of the Remuneration Committee, having recently purchased 509 shares in the company. These developments indicate active management of executive roles and shareholding, potentially impacting the company’s governance and stakeholder confidence.
Spirax Group plc has released its Annual Report and Accounts for 2024 and announced the date for its 2025 Annual General Meeting. The report highlights the company’s ongoing commitment to sustainability and innovation in industrial processes, with a focus on decarbonization and efficiency improvements. This announcement underscores Spirax Group’s strategic positioning in the market as a leader in enabling industrial transitions to net zero, which is expected to have a positive impact on its stakeholders and industry reputation.
Spirax Group plc announced that key executives, including Group CEO Nimesh Patel, CFO Louisa Burdett, and General Counsel Céline Barroche, have purchased shares in the company. These transactions, conducted on the London Stock Exchange, reflect a strategic move to align management interests with shareholders, potentially enhancing stakeholder confidence in the company’s future performance.